SixPeaks Bio

The company's primary focus is on addressing a significant side effect of popular GLP-1 receptor agonist-based obesity treatments: the loss of muscle mass along with fat. Up to 40% of weight lost using these drugs can be muscle, which can be detrimental, especially for older individuals. SixPeaks aims to preserve skeletal muscle mass during weight loss, thereby promoting a healthier body composition. The company operates within the competitive obesity treatment market, which is currently dominated by major pharmaceutical companies.

SixPeaks Bio's core technology revolves around an activin IIA/B receptor antibody. Inhibiting this signaling pathway has been shown to significantly increase muscle mass. Their lead product is a dual-specific antibody that targets these receptors to maintain muscle while a patient loses weight. Preclinical studies in mouse models have demonstrated that the company's lead molecules show strong efficacy in preserving muscle mass, both as a standalone therapy and in combination with GLP-1 agonists. Furthermore, the company has conjugated this antibody with a GLP-1 peptide, creating a potential first-in-class therapy designed to maximize fat loss while retaining muscle.

In May 2024, SixPeaks emerged from stealth with substantial financial backing. It secured $30 million in a Series A financing round led by Versant Ventures, with participation from AstraZeneca. Concurrently, it entered into a strategic collaboration with AstraZeneca, which committed up to an additional $80 million in non-dilutive financing over two years. This agreement gives AstraZeneca the exclusive option to acquire SixPeaks at a pre-agreed price upon the submission of an Investigational New Drug (IND) application for its lead candidate. Keywords: healthy weight loss, obesity treatment, muscle preservation, activin receptor antibody, GLP-1 agonist, biotechnology, cardiometabolic disease, Versant Ventures, AstraZeneca collaboration, dual-specific antibody, metabolic fitness, lean muscle mass, preclinical studies, Series A funding, drug discovery, biopharmaceutical, weight management solutions, skeletal muscle, polyfunctional products, metabolic fitness